Search Medical Condition
Please enter condition
Please choose location

Kampala, Uganda Clinical Trials

A listing of Kampala, Uganda clinical trials actively recruiting patients volunteers.

RESULTS

Found (9) clinical trials

Safety Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

This is a randomized, observer-blind, placebo-controlled, parallel-group, multicenter, 2-part, Phase 2 study Ad26.ZEBOV and MVA-BN-Filo in healthy and HIV infected adults. In part 1, prime vaccination with MVA-Bn-Filo will be followed by boost vaccination with Ad26 14 days later in the US. In part 2, two regimens will be investigated. ...

Phase

0.0 miles

Learn More »

A Study to Evaluate the Pharmacokinetics Safety Tolerability and Antiviral Efficacy of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

This is a Phase II, open-label (all people involved know the identity of the assigned drug) and single arm study. The study will consist of a screening period of maximum 8 weeks, an initial treatment period of 48 weeks, a post week 48 treatment extension period of 4 years, and ...

Phase

0.0 miles

Learn More »

Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study

Antiretroviral therapy (ART) in pregnancy is able to effectively reduce mother-to-child transmission (MTCT) of HIV. If untreated, the risk of transmission is around 25% (greater with high viral loads) but ART administered optimally during pregnancy may reduce this risk to 1-2%. In order to successfully prevent infection, ART should be ...

Phase

0.0 miles

Learn More »

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

This is a multi-country, prospective, long-term clinical safety study for collection of serious adverse events and pregnancy outcomes following administration of Ad26.ZEBOV and/or MVA-BN-Filo vaccines among participants who were enrolled in Phase 1, 2 or 3 clinical studies. The safety data will be collected in 3 cohorts; Cohort 1- adult ...

Phase

0.0 miles

Learn More »

Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid

Protocol Number: SSAT 062 EudraCT Number: 2014-002608-26 Name of Investigational Product: Sustiva/Stocrin/Atripla; Rifinah or local generic 300/150 Name of active ingredients: Efavirenz/ rifampicin/ isoniazid Study title:Steady-state pharmacokinetics of efavirenz (Sustiva/Stocrin) 400 mg once daily in the presence of rifampicin and isoniazid (Rifinah or the local generics) Name of Non Investigational ...

Phase

0.0 miles

Learn More »

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

This is a multi-country, prospective, long-term clinical safety study for collection of serious adverse events and pregnancy outcomes following administration of Ad26.ZEBOV and/or MVA-BN-Filo vaccines among participants who were enrolled in Phase 1, 2 or 3 clinical studies. The safety data will be collected in 3 cohorts; Cohort 1- adult ...

Phase

0.0 miles

Learn More »

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

PRIMARY OBJECTIVES: I. To determine the efficacy of a therapeutic escalation strategy consisting of standard dose nelfinavir (nelfinavir mesylate), followed by high dose nelfinavir, for the treatment of Kaposi sarcoma (KS) tumor lesions. With 36 evaluable participants, the null hypothesis will be rejected if 11 or more participants respond. SECONDARY ...

Phase

0.0 miles

Learn More »

EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure)

The Prevention Agent Pregnancy Exposure Registry, also known as EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure) is a prospective observational cohort study of maternal exposures to investigational HIV prevention agents. Approximately 550 pregnant participants and 400 live infants will be offered enrollment. The study population will ...

Phase N/A

0.0 miles

Learn More »

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

This is a Phase II/III trial to assess the short-term pharmacokinetics, safety, and tolerance of LPV/r in HIV-infected infants and children initiating LPV/r therapy who weigh >3 and <25 kg and are dosed according to the WHO antiretroviral (ARV) weight band dosing guidelines. LPV/r will be administered as the heat-stable ...

Phase

0.0 miles

Learn More »